Daiichi Sankyo to Expand Its Collaborative Drug Discovery Program to Germany, Switzerland, and Austria
29 July 2013 | By Daiichi Sankyo
Daiichi Sankyo announced that it will expand its Take a New challenge for Drug diScovery Global Program...
List view / Grid view
News
Novartis receives positive CHMP opinion for Ilaris®
26 July 2013 | By Novartis
Novartis announced that the CHMP of the EMA has adopted a positive opinion for the use of Ilaris® (canakinumab)...
Merck statement regarding CHMP review of incretin-based therapies for type 2 diabetes, including sitagliptin
26 July 2013 | By Merck
“Nothing is more important to us than the safety of our medicines..."
GSK receives positive CHMP opinion for REVOLADETM in thrombocytopenia associated with chronic hepatitis C infection
26 July 2013 | By GlaxoSmithKline
“A sustained virologic response is the goal for treatment of hepatitis C infection..."
Afatinib receives positive CHMP opinion for patients with EGFR mutation positive lung cancer in European Union
26 July 2013 | By Boehringer Ingelheim
"Boehringer Ingelheim welcomes the decision by the CHMP..."
Novartis first in class once-daily dual bronchodilator Ultibro® Breezhaler® (QVA149) gains positive CHMP opinion for the treatment of COPD
26 July 2013 | By Novartis
Novartis announced that the EMA's CHMP has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®...
Takeda receives positive CHMP opinion for three new type 2 diabetes therapies, VipidiaTM (alogliptin) and fixed-dose combinations VipdometTM (alogliptin-metformin) and IncresyncTM (alogliptin-pioglitazone)
26 July 2013 | By Virgo Health
“The number of people at risk from complications associated with type 2 diabetes continues to rise..."
US FDA acknowledges receipt of resubmission of the New Drug Application for investigational compound dapagliflozin for the treatment of type 2 diabetes
25 July 2013 | By AstraZeneca
The US FDA has acknowledged receipt of the NDA resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes...
Abbott receives FDA clearance for FreeStyle Precision Pro Blood Glucose and β–Ketone Monitoring System™
25 July 2013 | By Abbott
Abbott has received U.S. FDA clearance for its FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System™...
AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S
25 July 2013 | By AstraZeneca
NDA for dapagliflozin resubmitted to FDA...
First patient receives innovative new treatment to tackle combined diabetes and obesity in NHS approved trial
25 July 2013 | By Sanofi
Combined diabetes and obesity, ‘diabesity’, is a serious health problem...
UK children remain unnecessarily at risk for life-threatening and disabling meningitis B disease
24 July 2013 | By Novartis
Following JCVI interim recommendation on Novartis Bexsero® vaccine...
Merck announces FDA acceptance of New Drug Application for Vorapaxar
24 July 2013 | By Merck
Merck announced that the NDA for vorapaxar, has been accepted for standard review...
Roche’s obinutuzumab (GA101) delayed disease progression longer than MabThera/Rituxan in people with one of the most common forms of blood cancer
24 July 2013 | By Roche
Results from the phase III CLL11 study...
Bristol-Myers Squibb partners with the Centers for Disease Control Foundation
23 July 2013 | By Bristol-Myers Squibb Company
Joint effort supports early disease identification to connect at-risk patients to necessary care...
